Lakewood-Amedex to Showcase Nu-3 Diabetic Foot Ulcer Treatment at Investor Forum
Event summary
- Lakewood-Amedex CEO Kelvin Cooper to present at Life Sciences Virtual Investor Forum on June 25, 2026
- Focus on Nu-3 topical gel for infected diabetic foot ulcers (iDFU) advancing to Phase 2 trials
- Company highlights potential to address large, underserved patient population with antibiotic-resistant infections
- Bisphosphocin® platform targets MRSA, VRE, and other resistant bacterial strains
The big picture
Lakewood-Amedex's presentation comes as biotech investors increasingly focus on antimicrobial innovations amid growing antibiotic resistance. The company's Bisphosphocin® platform represents a novel approach in a field where few new classes of antibiotics have emerged in recent decades. Success with Nu-3 could position Lakewood-Amedex as a key player in treating infections that current therapies struggle to address.
What we're watching
- Clinical Milestones
- Whether Nu-3 can demonstrate efficacy in Phase 2 trials to validate its unique mechanism of action
- Market Opportunity
- The pace at which Lakewood-Amedex can capture share in the diabetic foot ulcer treatment market
- Regulatory Pathway
- How the FDA may view the Bisphosphocin® platform's broad-spectrum approach to antibiotic resistance
Related topics